Research Analysts Offer Predictions for ITCI FY2025 Earnings

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of Intra-Cellular Therapies in a research note issued to investors on Monday, February 24th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will post earnings of ($0.51) per share for the year, down from their previous estimate of ($0.25). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.64) per share.

Several other analysts have also commented on ITCI. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $140.00 to $132.00 in a research note on Monday. Ten equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Intra-Cellular Therapies has an average rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Trading Down 0.0 %

ITCI stock opened at $128.53 on Wednesday. Intra-Cellular Therapies has a 1-year low of $63.30 and a 1-year high of $128.77. The business’s 50 day moving average is $111.14 and its 200-day moving average is $90.22. The firm has a market cap of $13.67 billion, a P/E ratio of -147.73 and a beta of 0.72.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%.

Institutional Investors Weigh In On Intra-Cellular Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Avior Wealth Management LLC boosted its holdings in Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company’s stock valued at $327,000 after acquiring an additional 131 shares during the last quarter. M&T Bank Corp lifted its position in Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Intra-Cellular Therapies by 1.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 141 shares during the last quarter. CIBC Asset Management Inc grew its position in shares of Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 150 shares during the period. Finally, Pallas Capital Advisors LLC grew its position in shares of Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 192 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.60% of the stock is owned by insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.